In breast cancer, serum biomarkers (CA 15-3) combined with tumor-associated antigens and autoantibodies (heterogeneous nuclear ribonucleoproteins F and FTH1) can improve the accuracy of breast cancer diagnosis (Dong et al., 2013). Here, FTH1 is linked to breast carcinoma.